2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

653. Multiple Myeloma: Clinical and Epidemiological: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Omics Technologies, Pathology, Serologic Tests, Treatment Considerations, Combination Therapy, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Immunology, Immunodeficiency, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

2239 Real-world application of a FISH-adapted ims/IMWG 2025 genomic risk classification in newly diagnosed multiple myeloma: An ASH research collaborative data hub analysis

Hamza Hashmi, M.D., Shaji Kumar, MD2, Saad Z. Usmani, MD3, Aaron S Rosenberg, MD4, Kenneth Anderson, MD5, Shambavi Richard, MD6, Peter M Voorhees, MD7, Anita D'Souza Jr, MD8, Jodi Lipof, MD9, Arwa Bohra, MD10, Ajay K Nooka, MD, MPH11, Poy Theprungsirikul, MD12, Paul Gater, MPhil13, Michelle Ivy, MA14, Susan Geyer, PhD15, Peyton Schumacher16, Levi Pederson, MS17, Travis Dockter, MS18, Emily Semmel, MS19, Shandra James, DNP20, Samuel Rubinstein, MD MSCI21, William Wood, MD, MPH22, Marcella Kaddoura, MD23, Venkatesh Charya, MS24, LeAnn Ridling, CCRP25, Jiefu Wang, PhD26, Manisha Bhutani, MD27
1 Memorial Sloan Kettering, New York, United States
2 Mayo Clinic, Rochester, Rochester, Minnesota, United States
3 Memorial Sloan Kettering, New York, United States
4 University of California, Davis, School of Medicine, Sacramento, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Icahn School of Medicine at Mount Sinai, New York, New York, United States
7 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
8 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
9 University of San Francisco, San Francisco, California, United States
10 Mayo Clinic, Rochester, Rochester, Minnesota, United States
11 Emory University School of Medicine, Atlanta, Georgia, United States
12 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
13 ASH Research Collaborative, Washington, DC, United States
14 ASH Research Collaborative, Washington, DC, United States
15 Mayo Clinic, Rochester, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Rochester, Minnesota, United States
17 Mayo Clinic, Rochester, Rochester, Minnesota, United States
18 Mayo Clinic, Rochester, Rochester, Minnesota, United States
19 ASH Research Collaborative, Washington, DC, United States
20 ASH Research Collaborative, Washington, DC, United States
21 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
22 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
23 Karmanos Cancer Center, Detroit, Michigan, United States
24 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
25 Washington University School of Medicine in St. Louis, St. Louis, Missouri, United States
26 University of California, Davis, School of Medicine, Sacramento, United States
27 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States

Background: In 2025, the IMS/IMWG proposed a Consensus Genomic Staging (CGS) definition of high-risk (HR) newly diagnosed multiple myeloma (NDMM). Initial validation relied predominantly on NGS-based cytogenetic data from clinical trial populations. Because TP53 sequencing and biallelic del(1p32) assessment are not routinely available in practice, we applied a FISH-based modified CGS (mCGS) in a large real-world cohort and compared its performance with conventional FISH-based HR criteria. 

Methods: We identified patients with NDMM who had received first-line triplet or quadruplet regimens between 2015-2025 with FISH cytogenetics available within 30 days of diagnosis and response/survival data. Data were obtained from 12 US academic medical centers via the ASH Research Collaborative MM Data Hub (data cutoff May 27, 2026). Patients were classified as HR by conventional FISH criteria (del(17p), t(4;14), or t(14;16), per R-ISS 2015) and by mCGS (del(17p); or t(4;14), t(14;16), or t(14;20) co-occurring with 1q gain/amplification and/or del(1p); or 1q gain/amplification co-occurring with del(1p)). In the absence of these abnormalities within each criterion, patients were classified as standard risk (SR). TP53 mutation, biallelic del(1p32), and β2-microglobulin/creatinine criterion were not captured in the electronic case report form. OS and PFS were estimated using Kaplan-Meier methods and compared by institution-stratified log-rank tests.  

Results: Among 2,155 patients with NDMM, median age was 64.7 years, 56.1% were male, and 75.3% were White; 24.9% had received quadruplet therapy, with 31.6% frontline anti-CD38 antibody, and 35.5% autologous stem cell transplant. Median follow-up was 4.6 years with 223 deaths. By mCGS, 382 (17.7%) were HR; by conventional FISH criteria, 409 (19%) were HR; by R-ISS, 272/1,246 evaluable patients (21.8%) were stage III. 1q gain/amplification was the most common abnormality (672/2,155, 31.2%) and was more frequent among patients with R-ISS III than R-ISS I (46.7% vs 21.7%, p<0.001) and among those with del(1p) than those without (50.4% vs 29.8%, p<0.001). Quadruplet therapy was more common among patients with mCGS-HR than mCGS-SR (22.6% vs 16.1%, p=0.0007). HR distribution did not differ significantly by race (18.3% White vs 14.7% Black, p=0.22) or sex (16.5% male vs 19.3% female, p=0.08). 

Patients with mCGS-HR had significantly worse OS (5-year 78.8% vs 86.6%; hazard ratio (HR) 1.54, 95% CI 1.12-2.08, p=0.007) and PFS (3-year 56.9% vs 67.7%; HR 1.41, 95% CI 1.12-1.75, p=0.003) vs mCGS-SR. Patients with R-ISS III also had inferior outcomes vs R-ISS I (OS HR 3.53, 95% CI 1.94-6.42; PFS HR 2.04, 95% CI 1.38-3.03). mCGS reclassified 83/409 (20.3%) patients with conventional FISH-HR as SR, predominantly those with isolated IgH translocations ((60/164 [36.6%] with isolated t(4;14) and 25/69 [36.2%] with isolated t(14;16)) lacking co-occurring chromosome 1 abnormalities. Conversely, mCGS upgraded 56/1,746 (3.2%) patients with conventional FISH-SR to HR based on 1q gain/amplification co-occurring with del(1p). Among patients with conventional FISH-HR, those remaining mCGS-HR (n=221) had numerically worse OS (5-year 77.5% vs 87.8%; HR 1.57, 95% CI 0.74-3.35) and PFS (3-year 53.2% vs 58.2%; HR 1.35, 95% CI 0.79-2.31) than those reclassified to mCGS-SR (n=60), without reaching statistical significance. Patients with t(11;14) (n=365, 16.9%) were predominantly mCGS-SR (86.6%) with outcomes comparable to those without t(11;14). Among patients with mCGS-SR, isolated 1q gain/amplification (n =299, without co-occurring del(1p) or IgH translocation) when compared to those without 1q abnormalities was associated with worse OS (5-year 83.0% vs 87.7%; HR 1.45, 95% CI 1.03-2.04, p=0.032) but not PFS (3-year 69.3% vs 67.0%; HR 1.19, 95% CI 0.94-1.52, p=0.15).

Conclusions: In this large, diverse, real-world cohort; mCGS significantly stratified OS and PFS in NDMM. Among patients with conventional FISH-HR, mCGS reclassified ~20% as SR, supporting the prognostic value of co-occurrence-based risk assessment over isolated cytogenetic abnormalities. 1q gain/amplification was a key driver of mCGS-HR assignment through co-occurrence with IgH translocations and del(1p); while isolated 1q, classified as mCGS-SR, was still associated with inferior OS. These findings support the clinical utility of the IMS/IMWG 2025 cytogenetic framework applied using widely available FISH data in real-world practice. 

Hamza Hashmi, M.D.: Janssen Biotech - Consultancy (Includes expert testimony); Legend Biotech - Consultancy (Includes expert testimony)